Why I Founded Breeoot

I spent more than two decades as an entrepreneur and chairman — building and scaling ML-driven companies, working across high-growth environments, doing work that was intellectually demanding and commercially successful. By most measures, a strong run.

But one question kept coming back to me: what would it mean to apply what technology actually does well — continuous data processing, pattern recognition across large and complex datasets, systematic analysis over time — to the problem of keeping people healthy, rather than treating them after they're already sick?

In 2023, I partnered with Dr. Yair Schindel and Prof. Amir Tirosh to pursue that question seriously. Dr. Schindel brings deep experience at the intersection of healthcare and innovation; Prof. Tirosh is Chief Medical Officer of Breeoot and Head of Endocrinology at Sheba Medical Center, one of the most clinically rigorous people I know. Together, we developed a new model for evidence-based preventive and personalised medicine — and the system that became Breeoot.

The test that changed everything

To pressure-test the concept, I did something deliberate. I compiled my own medical records and shared them with several leading physicians — asking them to invest real time, analyse everything in front of them, and tell me what the data actually showed.

At that point, I had no symptoms. No chest pain, no shortness of breath, no prior cardiac events. My only documented condition was elevated LDL cholesterol, managed with statins. In years of routine annual check-ups — in both the United States and Israel — nobody had found anything to worry about. By every standard measure, I was unremarkable.

Two days after that review, my cardiologist called and asked me to come in for additional tests.

Ten days later, I underwent open-heart surgery. Four coronary bypass grafts.

What the data contained — and what it means

The cardiovascular risk that required that surgery had been building, silently, for years. It was present in the data — but only visible if you looked at the right markers, in the right combination, with the clinical knowledge to interpret them in context.

Among the findings was elevated Lp(a) — lipoprotein(a) — a particle that approximately one in five people carry at clinically significant levels. Lp(a) is atherogenic, prothrombotic, and pro-inflammatory: it deposits in arterial walls, competes with the body's clot-clearing mechanisms, and drives inflammation in ways that LDL cholesterol alone does not. It operates entirely independently of LDL — meaning a patient with a perfectly managed LDL reading can still carry a substantially elevated cardiovascular risk. And it is almost entirely genetic: no diet, no exercise programme, and no statin addresses it meaningfully. A single blood test is all it takes to identify it. The 2019 ESC/EAS guidelines recommend it be measured at least once in every adult's lifetime. Most physicians never order it.

What made this particularly significant in my own case: had I known my Lp(a) status five to seven years earlier, the clinical evidence suggests I could have avoided the bypass surgery entirely. PCSK9 inhibitors — monoclonal antibodies such as Repatha (evolocumab) and Praluent (alirocumab) — dramatically reduce LDL-C and also lower Lp(a) by approximately 25–30%, the most meaningful pharmacological reduction currently available. The FOURIER and ODYSSEY OUTCOMES trials both confirmed that patients with elevated baseline Lp(a) derive proportionally greater cardiovascular benefit from PCSK9 inhibition. Had I been on a PCSK9 inhibitor for the preceding years, the arterial plaque burden that required surgical intervention would likely never have reached that threshold. Today, my LDL-C is approximately 30 mg/dL. The medicine works — when you have the information in time.

To understand the science in depth, read our clinical article: Lp(a): The cardiac risk factor most physicians still don't routinely measure →

The second problem: no one connects the dots

After the surgery, I did what any thorough person would do. I ran a comprehensive health assessment — advanced metabolic markers, neurological evaluation, sleep medicine, multi-cancer early detection screening, genetic risk mapping. The medicine available at the frontier is genuinely remarkable. What I found in the process, however, was a second structural failure, as serious in its own way as the first.

Every specialist gave me a finding. Nobody connected them. The cardiologist was not in communication with the endocrinologist. The sleep physician was not calibrating with the metabolic team. Each result arrived in isolation, filed in a separate system, reviewed without context. The burden of synthesising all of it — understanding what each result meant in light of everything else, deciding what needed follow-up and in what order, coordinating between teams who had no shared view of my case — fell entirely on me. That burden was enormous. For most people, it is simply impossible.

This is not a failure of individual physicians. It is a structural failure of how medicine is organised. Specialists are designed to work in silos. There is no mechanism in standard care for longitudinal integration — for a single clinical mind to hold the complete picture over time and ask what it all means together.

Two problems. One mission.

The first problem: standard care systematically misses the markers that matter most — not because the tests don't exist, but because they are not in the workflow, not in the standard panel, and not what a six-minute GP appointment is designed to find.

The second problem: even when the tests are done, no one integrates the results. Each specialist sees a piece. Nobody sees the whole patient. And the patient is left to hold the burden of coordination that no individual without medical training should be expected to carry.

Breeoot is the answer to both.

We are a physician-led, data-driven preventive medicine system. We measure what standard care doesn't: advanced cardiovascular biomarkers including Lp(a), ApoB, and hs-CRP; metabolic markers including fasting insulin and continuous glucose; biological age via validated epigenetic clock analyses; genetic risk mapping through full exome sequencing; and multi-cancer early detection where clinically indicated. Every dimension of health, assessed with the tools and standards of the world's leading longevity programmes — Stanford, the Cleveland Clinic, Brigham and Women's.

And we integrate it. One physician holds your complete clinical picture — longitudinally, across every domain. Specialist coordination, continuous monitoring, lifestyle protocols grounded in your actual biology. Not a collection of separate opinions with no one connecting the dots — a single, coherent, continuously updated view of your health.

Two years in

The system we envisioned in 2023 is real. We have assembled a world-class medical, operational, and technology team. We are making significant, documented clinical impact on the lives of our members — finding what standard medicine is not looking for, in time to act on it.

My surgery was the event I would have done everything to prevent. The information that could have prevented it existed years before I was on an operating table. What didn't exist was a system designed to find it, interpret it, and act on it proactively.

That system now exists. That is Breeoot.